Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns

Türbachova, Ivana, Schwachula, Tim, Vasconcelos, Ines, Mustea, Alexander, Baldinger, Tina, Jones, Katherine A, Bujard, Hermann, Olek, Alexander, Olek, Klaus, Gellhaus, Katharina, Braicu, Ioana, Könsgen, Dominique, Fryer, Christy, Ravot, Elisabetta, Hellwag, Alexander, Westerfeld, Nicole, Gruss, Oliver J, Meissner, Markus, Hassan, Mazahir, Weber, Michael, Hoffmüller, Ulrich, Zimmermann, Sven, Loddenkemper, Christoph, Mahner, Sven, Babel, Nina, Berns, Els, Adams, Richard, Zeilinger, Robert, Baron, Udo, Vergote, Ignace, Maughan, Tim, Marme, Frederik, Dickhaus, Thorsten, Sehouli, Jalid and Olek, Sven 2013. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. Epigenetics 8 (11) , pp. 1226-1235. 10.4161/epi.26334

Full text not available from this repository.


The adaptive immune system is involved in tumor establishment and aggressiveness. Tumors of the ovaries, an immune-privileged organ, spread via transceolomic routes and rarely to distant organs. This is contrary to tumors of non-immune privileged organs, which often disseminate hematogenously to distant organs. Epigenetics-based immune cell quantification allows direct comparison of the immune status in benign and malignant tissues and in blood. Here, we introduce the “cellular ratio of immune tolerance” (immunoCRIT) as defined by the ratio of regulatory T cells to total T lymphocytes. The immunoCRIT was analyzed on 273 benign tissue samples of colorectal, bronchial, renal and ovarian origin as well as in 808 samples from primary colorectal, bronchial, mammary and ovarian cancers. ImmunoCRIT is strongly increased in all cancerous tissues and gradually augmented strictly dependent on tumor aggressiveness. In peripheral blood of ovarian cancer patients, immunoCRIT incrementally increases from primary diagnosis to disease recurrence, at which distant metastases frequently occur. We postulate that non-pathological immunoCRIT values observed in peripheral blood of immune privileged ovarian tumor patients are sufficient to prevent hematogenous spread at primary diagnosis. Contrarily, non-immune privileged tumors establish high immunoCRIT in an immunological environment equivalent to the bloodstream and thus spread hematogenously to distant organs. In summary, our data suggest that the immunoCRIT is a powerful marker for tumor aggressiveness and disease dissemination.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Centre for Trials Research (CNTRR)
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords: T lymphocytes, epigenetic immunophenotyping, immunoCRIT, ovarian cancer, regulatory T cells, tumor immunology, tumor metastasis
Publisher: Landes Bioscience
ISSN: 1559-2294
Last Modified: 04 Jun 2021 15:23

Citation Data

Cited 16 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item